Brief: Immunocore Presents Clinical Data Further Characterizing The Overall Survival Benefit Of Tebentafusp In Metastatic Uveal Melanoma At The 2021 American Society Of Clinical Oncology (Asco) Annual Meeting

Immunocore Holdings

04/06/2021 14:29

June 4 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE PRESENTS CLINICAL DATA FURTHER CHARACTERIZING
THE
OVERALL SURVIVAL BENEFIT OF TEBENTAFUSP IN METASTATIC UVEAL
MELANOMA AT THE 2021 AMERICAN SOCIETY OF CLINICAL ONCOLOGY
(ASCO) ANNUAL MEETING

Source text for Eikon:  ID:nGNE1VWPM4 
Further company coverage:  IMCR.O 

 ((reuters.briefs@thomsonreuters.com;))